Form 4: Cardlytics CFO Alexis DeSieno Reports Routine Stock Transactions Following RSU Vesting

Cardlytics Chief Financial Officer Alexis DeSieno reported the acquisition of 14,349 common shares through restricted stock unit vesting and the subsequent sale of 7,324 shares at a weighted average price of $1.7826 to cover tax obligations.

Summary

• Alexis DeSieno, Chief Financial Officer of Cardlytics, Inc. (CDLX), reported changes in beneficial ownership.
• On July 1, 2025, 14,349 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
• Following this, on July 2, 2025, 7,324 shares of common stock were sold at a weighted average price of $1.7826.
• The sale was exclusively to satisfy tax withholding obligations resulting from the RSU vesting.
• After these transactions, DeSieno directly beneficially owns 171,858 shares of common stock and 43,049 restricted stock units.
• The original RSU award was for 114,796 shares, vesting in eight equal installments from July 1, 2024, through April 1, 2026.

Sentiment

Score: 5

Explanation: The document reports routine insider transactions related to executive compensation (RSU vesting and tax-related sale), which are neutral events and do not indicate positive or negative company performance or outlook.

Positives

• The vesting of restricted stock units indicates the continued compensation and retention of a key executive, the Chief Financial Officer.
• The sale of shares was explicitly stated to be solely for tax withholding obligations, not for discretionary reasons, which is a routine and expected event for RSU vesting.

Negatives

• A reduction in direct beneficial ownership of common stock by 7,324 shares due to the sale, even if for tax purposes.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4. The document only details insider stock transactions.

Future Outlook

The remaining 43,049 restricted stock units are scheduled to vest in equal installments on October 1, 2025, January 1, 2026, and April 1, 2026, contingent on continued employment.

Management Comments

• Shares were sold solely to satisfy tax withholding obligations that resulted from the delivery of shares of common stock for RSUs that vested on July 1, 2025. The Reporting Person did not sell shares for any other purpose.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, specifically related to executive compensation through restricted stock units. It does not provide information on broader industry trends or competitive landscape. Such filings are common across all publicly traded companies where executives receive equity compensation.

Stakeholder Impact

• Shareholders: A minor, routine reduction in direct insider ownership due to tax-related sales, which is generally not a concern. The vesting of RSUs aligns executive incentives with shareholder value.
• Employees: The RSU vesting schedule indicates a structured compensation plan for executives, which can be a positive for employee retention and morale within the executive ranks.

Next Steps

• Future vesting of remaining Restricted Stock Units on October 1, 2025, January 1, 2026, and April 1, 2026, contingent on continued employment.

Key Dates

Keywords

Cardlytics, CDLX, Form 4, insider transaction, RSU vesting, stock sale, tax withholding, beneficial ownership, executive compensation, Alexis DeSieno, Chief Financial Officer